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Background-—Glycine is an amino acid involved in antioxidative reactions, purine synthesis, and collagen formation. Several
studies demonstrate inverse associations of glycine with obesity, hypertension, and diabetes mellitus. Recently, glycine-dependent
reactions have also been linked to lipid metabolism and cholesterol transport. However, little evidence is available on the
association between glycine and coronary heart disease. Therefore, we assessed the association between plasma glycine and
acute myocardial infarction (AMI).
Methods and Results-—A total of 4109 participants undergoing coronary angiography for suspected stable angina pectoris were
studied. Cox regression was used to estimate the association between plasma glycine and AMI, obtained via linkage to the
CVDNOR project. During a median follow-up of 7.4 years, 616 patients (15.0%) experienced an AMI. Plasma glycine was higher in
women than in men and was associated with a more favorable baseline lipid proﬁle and lower prevalence of obesity, hypertension,
and diabetes mellitus (all P<0.001). After multivariate adjustment for traditional coronary heart disease risk factors, plasma glycine
was inversely associated with risk of AMI (hazard ratio per SD: 0.89; 95% CI, 0.82–0.98; P=0.017). The inverse association was
generally stronger in those with apolipoprotein B, low-density lipoprotein cholesterol, or apolipoprotein A-1 above the median
(all Pinteraction≤0.037).
Conclusions-—Plasma glycine was inversely associated with risk of AMI in patients with suspected stable angina pectoris. The
associations were stronger in patients with apolipoprotein B, low-density lipoprotein cholesterol, or apolipoprotein A-1 levels above
the median. These results motivate further studies to elucidate the relationship between glycine and lipid metabolism, in particular
in relation to cholesterol transport and atherosclerosis.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00354081. ( J Am Heart Assoc. 2016;5:
e002621 doi: 10.1161/JAHA.115.002621)
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G lycine is a nonessential amino acid that can be obtainedeither via the diet, or synthesized endogenously from
serine, threonine, choline, or glyoxylate in the liver and
kidney.1 It is a predominant constituent of collagen and is
utilized in the synthesis of several biologically important
compounds, including glutathione, creatine, purines, and
glucose.2,3 Glycine exerts anti-inﬂammatory and antioxidative
effects4,5 and has been inversely associated with several
traditional cardiovascular risk factors, including obesity,6
hypertension,7,8 and diabetes mellitus.9
Increasing evidence suggests that glycine-dependent reac-
tions are associated with lipid homeostasis and cholesterol
transport. More speciﬁcally, glycine is utilized to catabolize
excess S-adenosylmethionine by its remethylation into sar-
cosine via the enzyme glycine-N-methyltransferase (GNMT),10
and excess hepatic S-adenosylmethionine concentrations
have been linked to the regulation of apolipoprotein (apo) B
mRNA expression and very low-density lipoprotein forma-
tion.11–13 Disturbances in these reactions have been associ-
ated with lipid accumulation both in the liver and in
macrophages, which further promotes oxidized low-density
lipoprotein (LDL)-induced foam cell formation in the artery
wall.12 Therefore, glycine availability may affect lipid metabo-
lism and thereby further modulate the risk of coronary artery
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disease (CAD). However, data on glycine and the risk of
atherosclerotic cardiovascular disease in observational stud-
ies are sparse.
We investigated the associations between plasma glycine
and incident acute myocardial infarction (AMI) in a large
cohort of patients with suspected stable angina pectoris, with
a particular focus on potential effect modiﬁcations by lipid
parameters. The results are reported according to
the STrengthening the Reporting of OBservational studies
in Epidemiology—Molecular Epidemiology (STROBE-ME)
guidelines.14
Materials and Methods
Study Population
The study population has been described previously.15 In
brief, a total of 4164 subjects underwent elective coronary
angiography for suspected stable angina pectoris during
2000–2004 at Haukeland (n=3413) or Stavanger (n=751)
University Hospitals in Western Norway. Among these
patients, 85 were taking folic acid supplementation while
583 were taking multivitamins before the study. In addition,
2573 (61.8%) were enrolled in the Western Norway B Vitamin
Intervention Trial (WENBIT; ClinicalTrials.gov Identiﬁer:
NCT00354081). Patients with missing baseline data on
plasma glycine (n=9), lipid parameters (n=1), or glycated
hemoglobin (n=45) were excluded, leaving a total of 4109
patients eligible for the current analyses.
The study protocol was in accordance with the Declara-
tion of Helsinki, and was approved by the Regional
Committee for Medical and Health Research Ethics, Western
Norway, the Norwegian Medicines Agency, and the Norwe-
gian Data Inspectorate. All patients provided written
informed consent.
Baseline Data
Clinical information and blood samples were obtained at
baseline before coronary angiography. Smoking status was
deﬁned according to self-reports and serum cotinine levels
(≥85 nmol/L) as previously described.16 Obesity was
deﬁned as body mass index (BMI) ≥30 kg/m2. Diabetes
mellitus was classiﬁed by self-reports, glucose measure-
ments (fasting plasma glucose ≥7.0 mmol/L or nonfasting
plasma glucose ≥11.1 mmol/L), or by single measurement
of glycated hemoglobin ≥6.5% according to the American
Diabetes Association guidelines.17 The extent of CAD at
angiography was scored 0 to 3 according to the number of
signiﬁcantly stenotic coronary arteries. Left ventricular
ejection fraction was determined by echocardiography or
ventriculography.
Clinical End Points
Study subjects were followed from enrollment until the onset
of AMI, or until the end of 2009. Information on clinical events
was collected from the Cardiovascular Disease in Norway
(CVDNOR; https://cvdnor.b.uib.no/) project, reporting on
patients being discharged with a cardiovascular disease
diagnosis from any of 42 Norwegian public hospitals from
1994 and throughout 2009.18,19 AMI (including fatal and
nonfatal AMI) as the primary end point was classiﬁed
according to the International Statistical Classiﬁcation of
Disease Tenth Revision (ICD-10) codes I21 and I22,
respectively.
Biochemical Analyses
Earlier reports have described the collection and storage of
blood samples and the biochemical analyses for relevant
clinical indices.15,16 In addition, plasma glycine was analyzed
by gas chromatography–tandem mass spectrometry20 at
Bevital A/S, Norway (www.bevital.no).
Statistical Analyses
Baseline categorical variables are reported as frequencies and
percentages, while continuous variables are presented as
medians with interquartile ranges. Plasma or serum metabo-
lite concentrations were log-transformed before statistical
analysis due to their right-skewed distributions. Baseline
variables across quartiles of plasma glycine of the whole
population were assessed by unadjusted median linear or
logistic regression for continuous and categorical variables,
respectively.
Cox regression analysis was used to estimate the associ-
ation between plasma glycine and risk of AMI. The risk
estimates were reported as ﬁfth versus ﬁrst plasma glycine
quintiles, trends across quintiles, and per 1 SD increment in
log-transformed plasma glycine. A simple survival model
(model I) was adjusted for age (continuous) and sex (male/
female). Covariates in the multivariate model (model II)
included age (continuous), sex (male/female), smoking
(yes/no), obesity (yes/no), hypertension (yes/no), diabetes
mellitus (yes/no), extent of CAD at angiography (ordinal),
statin treatment (yes/no), and estimated glomerular ﬁltration
rate, apolipoprotein A1 (apoA-1) and apoB (all continuous).
Since results from experimental studies suggest that glycine
may regulate pro-inﬂammatory cytokines,21,22 we additionally
included C-reactive protein (CRP) in an extended model.
Fasting status and baseline revascularization procedures had
negligible impact on the risk estimates and were excluded in
the ﬁnal model (data not shown). The assumption of
proportionality was examined by the Schoenfeld and scaled
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Schoenfeld residuals. Potential nonlinear dose–response
relationships between plasma glycine and risk of incident
AMI were visualized by generalized additive model plots for
both simple and multivariate models.
Potential effect modiﬁcations by prespeciﬁed lipid param-
eters (including serum apoB, LDL cholesterol, apoA1, and
high-density lipoprotein-cholesterol) were explored according
to their median values and tested by including an interaction
product term in Cox models adjusted for age, sex, and the use
of statins.
The statistical analyses were performed in R (R Core Team,
Vienna, Austria; version 3.1.1 & 3.1.2; packages “coin,”
“Hmisc,” “survival,” “MASS,” and “mgcv”). All reported P
values were 2-sided, and P<0.05 was considered signiﬁcant.
Table 1. Baseline Characteristics According to Quartiles of Plasma Glycine
Plasma Glycine Quartiles (lmol/L)
P for Trend1st (<178) 2nd (178–205) 3rd (205–243) 4th (>243)
Age, y 61 (14) 62 (14) 61 (15) 63 (16) 0.037
Male sex, n (%) 817 (79.5) 818 (79.7) 804 (78.2) 521 (50.7) <0.001
Current smoking, n (%) 299 (29.1) 292 (28.5) 375 (36.5) 337 (32.8) 0.003
Obesity, n (%) 321 (31.2) 183 (17.8) 135 (13.1) 113 (11.0) <0.001
Hypertension, n (%) 561 (54.6) 483 (47.1) 451 (43.9) 434 (42.3) <0.001
Diabetes mellitus, n (%) 513 (49.9) 413 (40.2) 393 (38.2) 393 (38.3) <0.001
HbA1c (%) 6.23 (1.77) 6.02 (1.56) 6.05 (1.33) 6.08 (1.42) <0.001
Serum
Apolipoprotein A1, mg/dL 1.24 (0.32) 1.28 (0.34) 1.31 (0.34) 1.37 (0.37) <0.001
Apolipoprotein B, mg/dL 0.90 (0.31) 0.88 (0.30) 0.85 (0.30) 0.85 (0.33) <0.001
HDL cholesterol, mmol/L 1.10 (0.30) 1.20 (0.40) 1.30 (0.42) 1.40 (0.50) <0.001
LDL cholesterol, mmol/L 3.00 (1.30) 2.99 (1.30) 2.90 (1.33) 2.90 (1.40) 0.064
eGFR, mL/min per 1.73 m2 94 (18) 92 (19) 91 (20) 86 (24) <0.001
Serum CRP, mg/L 2.48 (3.73) 1.84 (2.80) 1.58 (2.36) 1.35 (2.09) <0.001
Troponin T, ng/L 5 (8) 4 (6) 5 (7) 4 (6) 0.088
Prior MI, n (%) 438 (42.6) 436 (42.5) 437 (42.5) 347 (33.8) <0.001
LVEF (%) 65 (10) 65 (10) 65 (10) 65 (10) 0.092
Angiographic evidence of CAD, n (%)
No significant stenosis 189 (18.4) 214 (20.8) 260 (25.3) 374 (36.4) <0.001
Single-vessel disease 255 (24.8) 240 (23.4) 245 (23.8) 210 (20.4) 0.032
Double-vessel disease 250 (24.3) 249 (24.2) 228 (22.2) 188 (18.3) <0.001
Triple-vessel disease 334 (32.5) 323 (31.6) 295 (28.7) 255 (24.9) <0.001
Treatment following baseline coronary angiography, n (%)
No or medications only 413 (40.2) 424 (41.3) 468 (45.5) 565 (55.0) <0.001
PCI 374 (36.4) 357 (34.8) 337 (32.8) 283 (27.6) <0.001
CABG 229 (22.3) 230 (22.4) 209 (20.3) 157 (15.3) <0.001
Medications at discharge, n (%)
Aspirin 854 (83.1) 871 (84.9) 849 (82.6) 781 (76.0) <0.001
Statins 850 (82.7) 855 (83.3) 824 (80.2) 763 (74.3) <0.001
Beta blockers 774 (75.3) 764 (74.5) 749 (72.9) 694 (67.6) <0.001
ACEIs 237 (23.1) 233 (21.7) 202 (19.6) 178 (17.3) <0.001
Loop diuretics 141 (13.7) 102 (10.0) 88 (8.4) 119 (11.5) 0.075
Variables are given in medians (interquartile ranges) or counts (percentages). ACEIs, angiotensin-converting-enzyme inhibitors; CABG, coronary artery bypass graft surgery; CAD, coronary
artery disease; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; low-density lipoprotein; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Results
Patient Characteristics and Plasma Glycine
Levels at Baseline
The median (interquartile range) age for the 4109 patients at
baseline was 62 (15) years and 72.0% were males. As outlined
in Table 1, persons in the upper glycine quartiles were more
likely to be older, females, and smokers as compared to
persons in the lower quartiles. However, the association
between plasma glycine and smoking status was not signif-
icant after the adjustment for BMI (P=0.11). In addition,
persons in upper quartiles of plasma glycine also had higher
apoA-1 (P<0.001) and high-density lipoprotein-cholesterol
levels (P<0.001) and lower serum apoB (P<0.001) and glycine
tended to be associated with LDL cholesterol (P=0.064).
Notably, after adjusting for statin treatment, plasma glycine
was inversely associated with LDL cholesterol (P<0.001).
Plasma glycine was negatively associated with obesity,
hypertension, diabetes mellitus, serum CRP, and prior AMI.
We observed no association of plasma glycine with left
ventricular ejection fraction and cardiac high-sensitive tro-
ponin T, but a strong inverse association with the extent of
angiographic CAD, the latter also reﬂected by more use of
coronary heart disease medications among patients in the
lower plasma glycine quartiles.
Plasma Glycine and Risk of AMI
During a median (interquartile range) follow-up of 7.4 (2.4)
years, 616 patients (15.0%) experienced an AMI. After
adjusting for age and sex, higher plasma glycine was
associated with a decreased risk of AMI (hazard ratio per
SD: 0.88; 95% CI, 0.80–0.95; P=0.003). The association was
essentially similar after the multivariate adjustment (hazard
ratio per SD: 0.89; 95% CI, 0.82–0.98; P=0.017) (Table 2,
Figure 1). However, additional adjustment for plasma CRP
slightly attenuated the association between plasma glycine
and incident AMI (hazard ratio per SD: 0.92; 95% CI, 0.84–
1.01; P=0.085). Hazard ratios for AMI across all quintiles of
plasma glycine gave similar results and are given in Table 3.
Notably, nearly 62% of the patients were enrolled in the
WENBIT and randomly received treatments with folic acid plus
vitamin B12, vitamin B6, or placebo. The risk estimates of
plasma glycine in WENBIT were not modiﬁed by any
intervention treatments (all Pinteraction≥0.16, Table 4).
Subgroup Analyses
Figure 2 demonstrates the risk estimates between plasma
glycine and AMI occurrence according to several lipid param-
eters. We observed a stronger negative association between
plasma glycine and incident AMI among patients with high as
compared to low serum apoB and LDL cholesterol levels
(Pinteraction=0.037 and 0.012, respectively). Additionally, we
observed a stronger risk estimate of plasma glycine in patients
with high as compared to low apoA-1 levels (Pinteraction=0.027)
and a similar trend was also seen for high-density lipoprotein
cholesterol (Pinteraction=0.16). The estimates were essentially
similar after multivariate adjustment (Table 5).
Discussion
Principal Findings
In a large cohort of patients undergoing elective coronary
angiography for suspected stable angina pectoris, higher
plasma glycine was associated with a generally more
favorable cardiovascular disease risk factor proﬁle and with
a decreased risk of AMI during follow-up, independent of
traditional CAD risk factors. Furthermore, the inverse asso-
ciations between glycine and AMI were stronger among
patients with serum apoB, LDL cholesterol, or apoA-1 levels
above the median.
Plasma Glycine and Cardiovascular Disease
Consistent with our study, glycine has previously been
inversely associated with several coronary heart disease risk
factors, and in particular those related to insulin sensitivity,
glucose homeostasis, and the metabolic syndrome. Popula-
tion-based studies have demonstrated a positive association
of plasma glycine with estimated glucose disposal rate23 and a
negative association with glycated hemoglobin.24 Accordingly,
plasma glycine has been inversely associated with obesity,6,25
hypertension,8 and diabetes mellitus.9,26 Glycine intake has
also been associated with low plasma free fatty acids,
cholesterol and triglycerides levels in animal models.7,27
Table 2. Association Between Plasma Glycine and Acute
Myocardial Infarction
Hazard Ratio 95% CI P Value
Model I*
Per SD increment 0.88 0.80 to 0.95 0.003
Q5 vs Q1 0.68 0.52 to 0.88 0.004
Model II†
Per SD increment 0.89 0.82 to 0.98 0.017
Q5 vs Q1 0.71 0.54 to 0.94 0.016
*Adjusted for age and sex.
†Adjusted for age, sex, smoking, obesity, hypertension, diabetes mellitus angiographic
extent of coronary artery disease, estimated glomerular ﬁltration rate, apolipoprotein A-
1, apolipoprotein B, and statin treatment.
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Although high plasma glycinewas related to an overall favorable
coronary heart disease risk proﬁle, we somewhat unexpectedly
observed a positive association between plasma glycine and
smoking status. However, this relationshipmay be explained by
the negative correlation between BMI and smoking behavior,28
as adjusting for BMI rendered the association nonsigniﬁcant.
The relationships between glycine status and clinical cardio-
vascular end points have, to the best of our knowledge, not been
evaluated previously in large-scale observational studies; hence
the current study extends previous knowledge on cardiovascu-
lar prognosis according to glycine status.
Possible Mechanisms
The negative association between plasma glycine and LDL
cholesterol in the current study was probably veiled by the
intake of statins, since a greater proportion of patients in
lower plasma glycine quartiles were prescribed statins.
Accordingly, we observed a signiﬁcant inverse trend between
plasma glycine and LDL cholesterol after adjusting for statins,
in line with the inverse association with apoB, but positive
relationships with apoA-1and high-density lipoprotein choles-
terol. This suggests an important role of glycine in lipid
metabolism.
Figure 1. Dose–response associations between (log-transformed) plasma glycine and risk of acute
myocardial infarction. Generalized additive regressions are used with the adjustment for age and sex in the
simple model (A), and additional adjustment for smoking, obesity, hypertension, diabetes mellitus,
angiographic extent of coronary artery disease (ordinal), estimated glomerular ﬁltration rate, apolipoprotein
A-1, apolipoprotein B, and statin treatment in the multivariate model (B). The solid lines and the shaded
areas represent hazard ratios of plasma glycine and their 95% CI, respectively. The areas under the curve
along the X-axes represent the distributions of the plasma glycine concentrations (lmol/L) in the total
population. The vertical white lines denote the 25th, 50th, and 75th percentiles of plasma glycine,
respectively.
Table 3. Hazard Ratios (HR) of AMI According to Quintiles of
Plasma Glycine Levels
Model I* Model II†
HR (95% CI) P Value HR (95% CI) P Value
Quintiles
First Reference Reference
Second 0.89 (0.71–1.13) 0.34 0.93 (0.73–1.18) 0.54
Third 0.76 (0.59–0.97) 0.025 0.81 (0.63–1.04) 0.10
Fourth 0.80 (0.63–1.01) 0.062 0.83 (0.64–1.06) 0.13
Fifth 0.68 (0.52–0.88) 0.004 0.71 (0.54–0.94) 0.016
Trend 0.92 (0.87–0.97) 0.004 0.92 (0.87–0.98) 0.012
*Adjusted for age and sex.
†Adjusted for age, sex, smoking, obesity, hypertension, diabetes mellitus angiographic
extent of coronary artery disease, estimated glomerular ﬁltration rate, apolipoprotein
A-1, apolipoprotein B, and statin treatment.
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Indeed, considerable evidence suggests that glycine avail-
ability may be important in lipid metabolism and atheroscle-
rosis. First, glycine can be methylated into sarcosine via
GNMT, which is mainly conﬁned to the liver and kidney29,30;
however, rodent studies have shown that the GNMT is also
localized to aortic endothelial cells.12 Impaired GNMT ﬂux was
shown to exacerbate lipid accumulation in both the liver and
in macrophages, which can further promote oxidized LDL-
induced foam cell formation in the artery wall.12 Furthermore,
GNMT ﬂux has also been shown to affect composition of
atherosclerotic plaques and regulate inﬂammation response
within atherosclerotic lesions.12 We observed stronger asso-
ciations of glycine with AMI among those with higher apoB
and LDL cholesterol levels in subgroup analyses. This ﬁnding
may support the hypothesis that GNMT ﬂux plays a role in
plaques formation and the progression of atherosclerosis.
In addition, impaired GNMT ﬂux was suggested to interrupt
reverse cholesterol transport by downregulating the expres-
sion of scavenger receptors class B member 1 and ATP-binding
cassette transporters-A1 and G1.12 GNMT deﬁciency has also
been associated with hepatic cholesterol accumulation and
overt dyslipidemia by downregulation of Niemann-Pick type C2
protein,31 a regulator of intracellular cholesterol trafﬁcking and
homeostasis. In the same study, enhanced GNMT ﬂux was
shown to promote cholesterol export from the cells by
upregulating Niemann-Pick type C2, a process requiring the
involvement of lipid-poor apolipoproteins (apoA-1 and apoE),
which may explain the stronger beneﬁcial effect of plasma
glycine among patients with higher apoA-1 levels.
Moreover, reduced ﬂux over the GNMT pathway may cause
the accumulation of excess S-adenosylmethionine,10 which is
shown to interrupt hepatic apoB mRNA expression and very
low-density lipoprotein assembly.12,13 Accordingly, glycine
infusion normalized hepatic triglyceride-rich very low-density
lipoprotein secretion in rats fed a high-fat diet,32 suggesting
the necessity of adequate glycine status in avoiding hepatic
lipid accumulation, which is considered an independent
coronary heart disease risk factor.33
Plasma and tissue glycine concentrations are regulated by
the B6-dependent glycine cleavage system. Therefore, glycine
elevation may reﬂect B6 deﬁciency.34 Interestingly, low B6
status is suggested as a risk marker for CAD.35,36 However, in
part of our population who received B vitamin treatments, we
did not observe any signiﬁcant interaction between plasma
glycine and vitamin B6 on AMI occurrence. This ﬁnding may
indicate that the glycine-related atherogenesis may not be
solely dependent on pathways requiring vitamin B6.
Nevertheless, glycine has wide metabolic ramiﬁcations,
which therefore makes it difﬁcult to make conclusions on any
particular pathomechanism involved in the current study. For
instance, the negative correlation between plasma glycine and
CRP is in line with other studies,37,38 implying a role of glycineTa
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in inﬂammation. Indeed, glycine has been shown to directly
regulate the production of pro-inﬂammatory cytokines22,39
and has been suggested as a modulator of the pro-
inﬂammatory state.21 These ﬁndings may indicate the
involvement of glycine-related inﬂammation in atherogenesis
and can at least partly explain the attenuation of the risk
estimate of glycine when including serum CRP in the extended
Cox model.
Strengths and Limitations
The strengths of the study include the large sample size,
detailed baseline clinical characteristics, and its long-term
prospective design. Notably, a prior study from a subsample
of the current cohort showed that plasma glycine has an
excellent within-person reproducibility over time (intraclass
correlation coefﬁcient: 0.77 [95% CI: 0.74–0.79]),40 allowing
1-exposure assessment of biomarker status, as well as low
risk of regression-dilution bias.41
Several metabolic pathways contribute to glycine forma-
tion, and their relative quantitative contributions are not fully
elucidated. Glycine concentrations among individuals may
therefore be inﬂuenced by genetic and metabolic traits, as
well as dietary habits, which were not evaluated in the current
study. Hence, the possibility of residual confounding cannot
be excluded.
Conclusions
Plasma glycine was associated with decreased risk of AMI in
patients with suspected stable angina pectoris. This associ-
ation was particularly strong in those with apoB, LDL
cholesterol, or apoA-1 levels above the median. Our ﬁndings
Figure 2. Risk associations between plasma glycine and AMI according to the median values of
prespeciﬁed lipid parameters. The black squares represent the hazard ratios and their areas are
proportional to the subgroup sizes. Horizontal lines represent the 95% CI. AMI indicates acute myocardial
infarction; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
Table 5. Risk Associations Between Plasma Glycine and AMI
According to the Median Values of Prespeciﬁed Lipid
Parameters
HR (95% CI)* P Value Pint
HDL
Above median 0.86 (0.76–0.97) 0.017 0.22
Below median 0.96 (0.84–1.10) 0.58
ApoA-1
Above median 0.81 (0.71–0.93) 0.003 0.039
Below median 0.99 (0.87–1.12) 0.84
LDL
Above median 0.80 (0.70–0.91) <0.001 0.013
Below median 0.99 (0.87–1.13) 0.92
ApoB
Above median 0.81 (0.71–0.92) 0.002 0.032
Below median 0.99 (0.87–1.12) 0.84
AMI indicates acute myocardial infarction; HDL, high-density lipoprotein; HR, hazard
ratio; LDL, low-density lipoprotein.
*Adjusted for age, sex, smoking, obesity, hypertension, diabetes mellitus angiographic
extent of coronary artery disease, estimated glomerular ﬁltration rate, apolipoprotein
A-1, apolipoprotein B, and statin treatment.
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motivate further studies to elucidate the role of glycine in
regulating lipid metabolism and cholesterol transport in
patients with atherosclerosis.
Acknowledgments
The authors thank Reinhard Seifert and Arve Ulvik for statistical
assistance, and all the recruiting physicians and nurses for collecting
the clinical information, laboratory technicians and coworkers for
biochemical analyses at Haukeland University Hospital, Norway;
Stavanger University Hospital, Norway; and Bevital A/S, Norway. We
also thank Tomislav Dimoski at The Norwegian Knowledge Centre for
the Health Services, Oslo, Norway for his contribution by developing
the software necessary for obtaining data from Norwegian hospitals,
conducting the data collection, and quality assurance of data in this
project.
Sources of Funding
The present work has been funded by the University of
Bergen, the Department of Heart Disease, Haukeland Univer-
sity Hospital, Norway, the Western Norway Health Authority,
and the Foundation to Promote Research into Functional
Vitamin B12 Deﬁciency.
Disclosures
None.
References
1. Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals
and humans: implications for nutrition and health. Amino Acids. 2013;45:463–
477.
2. Hall JC. Glycine. JPEN J Parenter Enteral Nutr. 1998;22:393–398.
3. Gannon MC, Nuttall JA, Nuttall FQ. The metabolic response to ingested glycine.
Am J Clin Nutr. 2002;76:1302–1307.
4. Senthilkumar R, Sengottuvelan M, Nalini N. Protective effect of glycine
supplementation on the levels of lipid peroxidation and antioxidant enzymes in
the erythrocyte of rats with alcohol-induced liver injury. Cell Biochem Funct.
2004;22:123–128.
5. McCarty MF, DiNicolantonio JJ. The cardiometabolic beneﬁts of glycine: is
glycine an ‘antidote’ to dietary fructose? Open Heart. 2014;1:e000103.
6. Oberbach A, Bluher M, Wirth H, Till H, Kovacs P, Kullnick Y, Schlichting N,
Tomm JM, Rolle-Kampczyk U, Murugaiyan J, Binder H, Dietrich A, von Bergen
M. Combined proteomic and metabolomic proﬁling of serum reveals
association of the complement system with obesity and identiﬁes novel
markers of body fat mass changes. J Proteome Res. 2011;10:4769–4788.
7. El Haﬁdi M, Perez I, Zamora J, Soto V, Carvajal-Sandoval G, Banos G. Glycine
intake decreases plasma free fatty acids, adipose cell size, and blood pressure
in sucrose-fed rats. Am J Physiol Regul Integr Comp Physiol. 2004;287:1387–
1393.
8. El Haﬁdi M, Perez I, Banos G. Is glycine effective against elevated blood
pressure? Curr Opin Clin Nutr Metab Care. 2006;9:26–31.
9. De Luca G, Calpona PR, Caponetti A, Macaione V, Di Benedetto A, Cucinotta D,
Di Giorgio RM. Preliminary report: amino acid proﬁle in platelets of diabetic
patients. Metabolism. 2001;50:739–741.
10. Mudd SH, Brosnan JT, Brosnan ME, Jacobs RL, Stabler SP, Allen RH, Vance DE,
Wagner C. Methyl balance and transmethylation ﬂuxes in humans. Am J Clin
Nutr. 2007;85:19–25.
11. Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, Tsai TF, Hsiao M, Huang
SF, Chen YM. Glycine N-methyltransferase/ mice develop chronic
hepatitis and glycogen storage disease in the liver. Hepatology.
2007;46:1413–1425.
12. Chen CY, Ching LC, Liao YJ, Yu YB, Tsou CY, Shyue SK, Chen YM, Lee TS.
Deﬁciency of glycine N-methyltransferase aggravates atherosclerosis in
apolipoprotein E-null mice. Mol Med. 2012;18:744–752.
13. Martinez-Una M, Varela-Rey M, Mestre D, Fernandez-Ares L, Fresnedo O,
Fernandez-Ramos D, Juan VG, Martin-Guerrero I, Garcia-Orad A, Luka Z,
Wagner C, Lu SC, Garcia-Monzon C, Finnell RH, Aurrekoetxea I, Buque X,
Martinez-Chantar ML, Mato JM, Aspichueta P. S-Adenosylmethionine increases
circulating very-low density lipoprotein clearance in non-alcoholic fatty liver
disease. J Hepatol. 2014;62:673–681.
14. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M,
Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M,
Vineis P. STrengthening the Reporting of OBservational studies in Epidemi-
ology—Molecular Epidemiology (STROBE-ME): an extension of the STROBE
statement. Eur J Clin Invest. 2012;42:1–16.
15. Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, Midttun
O, Meyer K, Mellgren G, Ulvik A, Nordrehaug JE, Nilsen DW, Nygard O.
Associations of plasma kynurenines with risk of acute myocardial infarction in
patients with stable angina pectoris. Arterioscler Thromb Vasc Biol.
2015;35:455–462.
16. Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing
M, Loland KH, Tell GS, Nygard O. Plasma dimethylglycine and risk of incident
acute myocardial infarction in patients with stable angina pectoris. Arterioscler
Thromb Vasc Biol. 2013;33:2041–2048.
17. American Diabetes A. Diagnosis and classiﬁcation of diabetes mellitus.
Diabetes Care. 2010;33:S62–S69.
18. Sulo G, Igland J, Nygard O, Vollset SE, Ebbing M, Tell GS. Favourable trends in
incidence of AMI in Norway during 2001–2009 do not include younger adults:
a CVDNOR project. Eur J Prev Cardiol. 2014;21:1358–1364.
19. Sulo G, Igland J, Vollset SE, Nygard O, Øyen N, Tell GS. Cardiovascular disease
and diabetes mellitus in Norway during 1994–2009 CVDNOR—a nationwide
research project. Norsk Epidemiol. 2013;23:101–107.
20. Windelberg A, Arseth O, Kvalheim G, Ueland PM. Automated assay for the
determination of methylmalonic acid, total homocysteine, and related amino
acids in human serum or plasma by means of methylchloroformate
derivatization and gas chromatography-mass spectrometry. Clin Chem.
2005;51:2103–2109.
21. Garcia-Macedo R, Sanchez-Munoz F, Almanza-Perez JC, Duran-Reyes G,
Alarcon-Aguilar F, Cruz M. Glycine increases mRNA adiponectin and dimin-
ishes pro-inﬂammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol.
2008;587:317–321.
22. Almanza-Perez JC, Alarcon-Aguilar FJ, Blancas-Flores G, Campos-Sepulveda AE,
Roman-Ramos R, Garcia-Macedo R, Cruz M. Glycine regulates inﬂammatory
markers modifying the energetic balance through PPAR and UCP-2. Biomed
Pharmacother. 2010;64:534–540.
23. Thalacker-Mercer AE, Ingram KH, Guo F, Ilkayeva O, Newgard CB, Garvey WT.
BMI, RQ, diabetes, and sex affect the relationships between amino acids and
clamp measures of insulin action in humans. Diabetes. 2014;63:791–800.
24. Zhou Y, Qiu L, Xiao Q, Wang Y, Meng X, Xu R, Wang S, Na R. Obesity and
diabetes related plasma amino acid alterations. Clin Biochem. 2013;46:1447–
1452.
25. Tastesen HS, Keenan AH, Madsen L, Kristiansen K, Liaset B. Scallop protein
with endogenous high taurine and glycine content prevents high-fat, high-
sucrose-induced obesity and improves plasma lipid proﬁle in male C57BL/6J
mice. Amino Acids. 2014;46:1659–1671.
26. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, Heim K,
Campillos M, Holzapfel C, Thorand B, Grallert H, Xu T, Bader E, Huth C,
Mittelstrass K, D€oring A, Meisinger C, Gieger C, Prehn C, Roemisch-Margl W,
Carstensen M, Xie L, Yamanaka-Okumura H, Xing G, Ceglarek U, Thiery J, Giani
G, Lickert H, Lin X, Li Y, Boeing H, Joost H-G, de Angelis MH, Rathmann W,
Suhre K, Prokisch H, Peters A, Meitinger T, Roden M, Wichmann HE, Pischon T,
Adamski J, Illig T. Novel biomarkers for pre-diabetes identiﬁed by
metabolomics. Mol Syst Biol. 2012;8:615.
27. Park T, Lee K. Dietary taurine supplementation reduces plasma and liver
cholesterol and triglyceride levels in rats fed a high-cholesterol or a
cholesterol-free diet. Adv Exp Med Biol. 1998;442:319–325.
28. Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. III.
Effects of cigarette smoking. JAMA. 1989;261:1169–1173.
29. Kerr SJ. Competing methyltransferase systems. J Biol Chem. 1972;247:4248–
4252.
30. Yeo EJ, Wagner C. Tissue distribution of glycine N-methyltransferase, a major
folate-binding protein of liver. Proc Natl Acad Sci USA. 1994;91:210–214.
31. Liao Y, Chen T, Lee T, Wang H, Wang C, Liao L, Liu R, Huang S, Chen YA.
Glycine N-methyltransferase deﬁciency affects Niemann-Pick type C2 protein
DOI: 10.1161/JAHA.115.002621 Journal of the American Heart Association 8
Plasma Glycine and Risk of AMI Ding et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 22, 2016http://jaha.ahajournals.org/Downloaded from 
stability and regulates hepatic cholesterol homeostasis. Mol Med.
2012;18:412–422.
32. Yue JT, Mighiu PI, Naples M, Adeli K, Lam TK. Glycine normalizes hepatic
triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats. Circ
Res. 2012;110:1345–1354.
33. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
34. Davis SR, Scheer JB, Quinlivan EP, Coats BS, Stacpoole PW, Gregory JF III.
Dietary vitamin B-6 restriction does not alter rates of homocysteine
remethylation or synthesis in healthy young women and men. Am J Clin Nutr.
2005;81:648–655.
35. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P,
Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. Low circulating folate
and vitamin B6 concentrations: risk factors for stroke, peripheral vascular
disease, and coronary artery disease. European COMAC Group. Circulation.
1998;97:437–443.
36. Friso S, Girelli D, Martinelli N, Olivieri O, Lotto V, Bozzini C, Pizzolo F,
Faccini G, Beltrame F, Corrocher R. Low plasma vitamin B-6 concentrations
and modulation of coronary artery disease risk. Am J Clin Nutr.
2004;79:992–998.
37. Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimburger
O, Anderstam B, Rodriguez Ayala E, Divino Filho JC, Alvestrand A, Lindholm B.
Inﬂammation contributes to low plasma amino acid concentrations in patients
with chronic kidney disease. Am J Clin Nutr. 2005;82:342–349.
38. Wheeler MD, Ikejema K, Enomoto N, Stacklewitz RF, Seabra V, Zhong Z, Yin M,
Schemmer P, Rose ML, Rusyn I, Bradford B, Thurman RG. Glycine: a new anti-
inﬂammatory immunonutrient. Cell Mol Life Sci. 1999;56:843–856.
39. Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, Sanchez-Barrera R,
Wacher NH, Carvajal-Sandoval G, Kumate J. Glycine treatment decreases
proinﬂammatory cytokines and increases interferon-c in patients with type 2
diabetes. J Endocrinol Invest. 2008;31:694–699.
40. Midttun O, Townsend MK, Nygard O, Tworoger SS, Brennan P, Johansson M,
Ueland PM. Most blood biomarkers related to vitamin status, one-carbon
metabolism, and the kynurenine pathway show adequate preanalytical stability
and within-person reproducibility to allow assessment of exposure or
nutritional status in healthy women and cardiovascular patients. J Nutr.
2014;144:784–790.
41. Frost C, Thompson SG. Correcting for regression dilution bias: comparison of
methods for a single predictor variable. J R Stat Soc Ser A. 2000;163:173–189.
DOI: 10.1161/JAHA.115.002621 Journal of the American Heart Association 9
Plasma Glycine and Risk of AMI Ding et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 22, 2016http://jaha.ahajournals.org/Downloaded from 
and Ottar K. Nygård
Yunpeng Ding, Gard F. T. Svingen, Eva R. Pedersen, Jesse F. Gregory, Per M. Ueland, Grethe S. Tell
Angina Pectoris
Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.115.002621
2016;5:e002621; originally published December 31, 2015;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/5/1/e002621
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on February 22, 2016http://jaha.ahajournals.org/Downloaded from 
